H. Lundbeck (LUN) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
18 Mar, 2026Opening remarks and agenda
The meeting was opened with a welcome, highlighting hybrid attendance options and simultaneous interpretation for inclusivity.
Chair of the Board welcomed attendees and outlined the agenda, including financial review, board elections, remuneration, shareholder proposals, and other business.
The agenda included reports on company activities, annual report adoption, profit appropriation, remuneration, board elections, auditor appointment, shareholder and board proposals, and other business.
Confirmation was given that the AGM was lawfully convened, with 86% of share capital and almost 87% of votes represented.
Financial performance review
Record revenues were achieved for the fourth consecutive year, with 2025 revenues reaching DKK 24,630 million, up 13% at constant exchange rates.
Adjusted EBITDA increased by 24% to over DKK 7.8 billion, with a margin of 32%; EBITDA up 38%.
Strategic products and brands, including Vyepti and Rexulti, grew by 19% at constant exchange rates, driving double-digit growth and making up 77% of total revenues.
Strong cash flow from operations (DKK 5.5 billion) enabled rapid deleveraging, reducing net leverage to 1.2x.
Share price rose 4.5% in 2025, outperforming the OMXC25 index, but declined 9.9% YTD 2026 amid geopolitical headwinds.
Board and executive committee updates
The Board consists of seven re-elected members and one new member, Rita Balice-Gordon, who brings deep neuroscience and rare disease expertise.
The executive leadership team, in place since August 2024, includes a newly appointed Chief AI Officer to accelerate digital transformation.
Employee-elected board members were thanked for their service, with most re-elected and a new member introduced.
Latest events from H. Lundbeck
- Strong growth, innovation, and capital discipline drive long-term value and shareholder returns.LUN
Investor update - H1 2026 saw 16% CER revenue growth, strong brand and pipeline momentum, and guidance maintained.LUN
Q2 2026 - H1 2026 revenue up 16% CER, strong cash flow, and robust growth from Vyepti and Rexulti.LUN
Q2 2026 - Bocunebart showed strong efficacy and safety in migraine prevention, advancing to Phase III.LUN
Study update - Q1 2026 saw 21% CER revenue growth, margin expansion, and upgraded full-year guidance.LUN
Q1 2026 - Q1 2026 saw 21% CER revenue growth, margin expansion, and upgraded full-year guidance.LUN
Q1 2026 - 13% revenue growth and strong EBITDA in 2025, with robust outlook for 2026.LUN
Q4 2025 - Raised 2025 guidance after double-digit revenue and profit growth, led by Vyepti and Rexulti.LUN
Q2 2025 - Transformative year with late-stage pipeline advances and disciplined capital allocation.LUN
43rd Annual J.P. Morgan Healthcare Conference